Premium
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB / II study
Author(s) -
Phillips Tycel,
Brunvand Mark,
Chen Andy I.,
Essell James,
Chiappella Annalisa,
Diefenbach Catherine,
Cheng Ji,
Ramies David,
Hirata Jamie,
Morschhauser Franck,
Flinn Ian W.
Publication year - 2022
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26400
Subject(s) - medicine , obinutuzumab , tolerability , rituximab , oncology , bendamustine , antibody drug conjugate , lymphoma , phases of clinical research , follicular lymphoma , refractory (planetary science) , gastroenterology , chemotherapy , immunology , adverse effect , monoclonal antibody , antibody , biology , astrobiology